Literature DB >> 3521712

Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation.

J Patterson, H G Prentice, M K Brenner, M Gilmore, G Janossy, K Ivory, D Skeggs, H Morgan, J Lord, H A Blacklock.   

Abstract

Bone marrow graft rejection following HLA-matched bone marrow transplantation (BMT) for leukaemia has been a rare problem. However, with the introduction of T-lymphocyte depleted BMT, graft rejection is recognized as a new complication. At the Royal Free Hospital (RFH) in London T-depletion is achieved using two monoclonal antibodies with complement mediated lysis. The methodology was extended to other centres and in total 56 patients have received T-depleted, HLA matched BMT. Twelve of 56 patients have had graft rejection. At the RFH three of 41 (7%) patients have had rejection whereas at collaborating centres nine of 15 (60%) patients have had rejection. We have investigated these rejections in order to identify factor(s) responsible. Rejection was not restricted by patient or donor characteristics, nor disease status. Patient management, chemotherapy conditioning, efficiency of T-depletion, graft versus host disease (GvHD), and infection post BMT, were not consistently implicated. The major difference between the RFH and all other centres was in the radiotherapy (RT) conditioning: The RFH prescribed a single fraction of 7.5 Gy total body irradiation (TBI) whilst collaborating centres gave 10 or 12 Gy fractionated TBI. We conclude that the different incidence of rejection (7% v. 60%) relates primarily to the RT conditioning although the mechanisms(s) of rejection remain unknown. We conclude that where T-depleted BMT is used, compensation by more intensive RT conditioning is required in order to avert graft rejection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3521712     DOI: 10.1111/j.1365-2141.1986.tb05544.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

Review 1.  Tolerance induction for solid organ grafts with donor-derived hematopoietic reconstitution.

Authors:  K L Gandy
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.

Authors:  T Ruutu; A Gratwohl; T de Witte; B Afanasyev; J Apperley; A Bacigalupo; F Dazzi; P Dreger; R Duarte; J Finke; L Garderet; H Greinix; E Holler; N Kröger; A Lawitschka; M Mohty; A Nagler; J Passweg; O Ringdén; G Socié; J Sierra; A Sureda; W Wiktor-Jedrzejczak; A Madrigal; D Niederwieser
Journal:  Bone Marrow Transplant       Date:  2013-07-29       Impact factor: 5.483

3.  Lymphocyte populations in autopsy bone marrow sections from recipients of allogeneic marrow and non-transplant sudden death cases.

Authors:  S A Dilly; C J Jagger; J P Sloane
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

Review 4.  Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Authors:  Abhinav Deol; Lawrence G Lum
Journal:  Cancer Treat Rev       Date:  2010-04-09       Impact factor: 12.111

5.  Applications of bone marrow transplantation.

Authors:  S R McCann
Journal:  Ir J Med Sci       Date:  1988-03       Impact factor: 1.568

6.  Future directions of bone marrow transplantation.

Authors:  N A Buskard
Journal:  CMAJ       Date:  1987-08-15       Impact factor: 8.262

7.  Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.

Authors:  Elizabeth O Hexner; Selina M Luger; Ran Reshef; Grace R Jeschke; James K Mangan; Noelle V Frey; Dale M Frank; Lee P Richman; Robert H Vonderheide; Nicole A Aqui; Misha Rosenbach; Yi Zhang; Anne Chew; Alison W Loren; Edward A Stadtmauer; Bruce L Levine; Carl H June; Stephen G Emerson; David L Porter
Journal:  Am J Hematol       Date:  2016-04-04       Impact factor: 10.047

8.  Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow.

Authors:  T Schmeiser; M Wiesneth; D Bunjes; R Arnold; B Hertenstein; W Heit; E Kurrle
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

9.  Ifosfamide and ACNU in experimental allogeneic bone marrow transplantation.

Authors:  W Gassmann; A Erbersdobler; L Uharek; B Glass; H Löffler; W Mueller-Ruchholtz
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant.

Authors:  Alok Gupta; Sachin Punatar; Jayant Gawande; Libin Mathew; Bhausaheb Bagal; Sadhana Kannan; Navin Khattry
Journal:  Indian J Hematol Blood Transfus       Date:  2015-01-07       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.